A cost-effectiveness analysis of nivolumab versus docetaxel for advanced non-squamous non-small cell lung cancer including PD-L1 testing

[1]  N. Leighl,et al.  Pointed Progress in Second-Line Advanced Non-Small-Cell Lung Cancer: The Rapidly Evolving Field of Checkpoint Inhibition. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  C. la Vecchia,et al.  The global decrease in cancer mortality: trends and disparities. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  Keunchil Park,et al.  Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial , 2016, The Lancet.

[4]  Gideon Blumenthal,et al.  FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy , 2016, The oncologist.

[5]  R. Goeree,et al.  Economic evaluation of nivolumab for the treatment of second-line advanced squamous NSCLC in Canada: a comparison of modeling approaches to estimate and extrapolate survival outcomes , 2016, Journal of medical economics.

[6]  D. Ettinger,et al.  NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 4.2016. , 2016, Journal of the National Comprehensive Cancer Network : JNCCN.

[7]  R. Braun,et al.  Treatment specific utility‐weightings are needed for cost–utility analysis in metastatic melanoma: reply from the authors , 2016, The British journal of dermatology.

[8]  P. Fernández-Peñas,et al.  Treatment‐specific utility weightings are needed for cost–utility analysis in metastatic melanoma , 2016, The British journal of dermatology.

[9]  L. Saltz.  Perspectives on Cost and Value in Cancer Care. , 2016, JAMA oncology.

[10]  S. Temin,et al.  Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. , 2016, Journal of oncology practice / American Society of Clinical Oncology.

[11]  J. Wolchok,et al.  Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  C. Marquette,et al.  Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  T. Zeltner,et al.  Individual Responsibility and Community Solidarity--The Swiss Health Care System. , 2015, The New England journal of medicine.

[14]  R. Braun,et al.  A cost‐effectiveness analysis of trametinib plus dabrafenib as first‐line therapy for metastatic BRAF V600‐mutated melanoma in the Swiss setting , 2015, The British journal of dermatology.

[15]  C. Rudin,et al.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[16]  S. Peters,et al.  [Is prescription of a therapy costing 150,000 CHF reasonable?]. , 2015, Revue medicale suisse.

[17]  M. Piccart,et al.  A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  L. Crinò,et al.  Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[19]  Adam P Dicker,et al.  American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Matteo Brunelli,et al.  Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers , 2015, PloS one.

[21]  K. Dwan,et al.  Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluation. , 2015, Health technology assessment.

[22]  J. Lunceford,et al.  Pembrolizumab for the treatment of non-small-cell lung cancer. , 2015, The New England journal of medicine.

[23]  E. Berndt,et al.  Pricing in the Market for Anticancer Drugs , 2014, The journal of economic perspectives : a journal of the American Economic Association.

[24]  Masahiko Ando,et al.  Randomized phase III trial of erlotinib versus docetaxel as second- or third-line therapy in patients with advanced non-small-cell lung cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA). , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  H. Kantarjian,et al.  High cancer drug prices in the United States: reasons and proposed solutions. , 2014, Journal of oncology practice.

[26]  D De Ruysscher,et al.  Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[27]  Mark R. Green,et al.  Cost effectiveness of first-line pemetrexed plus platinum compared with other regimens in the treatment of patients with nonsquamous non-small cell lung cancer in the US outpatient setting. , 2013, Lung cancer.

[28]  G. Giaccone,et al.  Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial. , 2013, The Lancet. Oncology.

[29]  M J Buxton,et al.  Systematic review and meta-analysis of the growth and rupture rates of small abdominal aortic aneurysms: implications for surveillance intervals and their cost-effectiveness. , 2013, Health technology assessment.

[30]  C. Tudur-Smith,et al.  Clinical effectiveness and cost-effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer: a systematic review and economic evaluation. , 2013, Health technology assessment.

[31]  G. Pilkington,et al.  Clinical effectiveness of first-line chemoradiation for adult patients with locally advanced non-small cell lung cancer: a systematic review. , 2013, Health technology assessment.

[32]  David C. Smith,et al.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.

[33]  D. Dunlop,et al.  A Cost-Effectiveness Analysis of Docetaxel in the Second-Line Treatment of Non-Small Cell Lung Cancer , 2012, PharmacoEconomics.

[34]  M. Joerger,et al.  Cost-effectiveness of maintenance pemetrexed in patients with advanced nonsquamous-cell lung cancer from the perspective of the Swiss health care system. , 2012, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[35]  J. Pignon,et al.  Cost-effectiveness of three strategies for second-line erlotinib initiation in nonsmall-cell lung cancer: the ERMETIC study part 3 , 2011, European Respiratory Journal.

[36]  M. Joerger,et al.  Addition of cetuximab to first-line chemotherapy in patients with advanced non-small-cell lung cancer: a cost-utility analysis. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[37]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[38]  M. Peake,et al.  Cost-Effectiveness of Erlotinib versus Docetaxel for Second-Line Treatment of Advanced Non-Small-Cell Lung Cancer in the United Kingdom , 2010, The Journal of international medical research.

[39]  D. Cerny,et al.  Lung Cancer in the Canton of St. Gallen, Eastern Switzerland: Sex-Associated Differences in Smoking Habits, Disease Presentation and Survival , 2009, Oncology Research and Treatment.

[40]  E. Erdmann,et al.  Cost-effectiveness of pioglitazone in patients with type 2 diabetes and a history of macrovascular disease in a Swiss setting. , 2009, Swiss medical weekly.

[41]  Miklos Pless,et al.  Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  Michael E. Chernew,et al.  Willingness to Pay for a Quality-adjusted Life Year , 2000, Medical decision making : an international journal of the Society for Medical Decision Making.

[43]  J. Dancey,et al.  Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  D. Ettinger,et al.  Metastatic non-small cell lung cancer , 1993 .